

To,

GILEAD SCIENCES, INC.,
333 Lakeside Drive
Foster City, CA 94404
United States of America

MEDICINES PATENT POOL,
Chemin Louis-Dunant 17
1202 Geneva
Switzerland

October 2, 2015

Dear Sir,

SUB: Termination Notice for Tenofovir Disoproxil Fumarate

ATTENTION: General Counsel

This is with reference to the First Amended and Restated License Agreement dated October 1, 2015 executed between Gilead Sciences, Inc., Medicines Patent Pool and Cipla Limited ("License Agreement").

According to Section 10.5 of the License Agreement, Cipla Limited shall have the right, at its sole discretion, to terminate the licenses granted with respect to any particular Active Pharmaceutical Ingredient. Accordingly, please consider this letter as a notice of termination of the License Agreement with respect to tenofovir disoproxil fumarate and all combination products containing tenofovir disoproxil fumarate. The foregoing termination shall be effective as of the date of this letter.

For Cipla Limited,



A handwritten signature in blue ink, appearing to be "Subhanu Saxena", written over a horizontal line.

Name: Subhanu Saxena
Title: Global Chief Executive Officer

